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Abstract Mitochondrial transcription factor A (mtTFA) is
necessary for both transcription and maintenance of
mitochondrial DNA. This study was conducted to elucidate
the clinicopathologic and prognostic significance of mtTFA
in patients with endometrial carcinoma. This study inves-
tigated the relationship between the immunohistochemical
expression of mtTFA and various clinicopathological
variables in 276 endometrial carcinomas, including 245
endometrioid adenocarcinomas and 31 nonendometrioid
carcinomas (21 serous carcinomas and 10 clear cell
adenocarcinomas). Both uni- and multivariate regression
analyses were performed. The mtTFA labeling index of
endometrioid adenocarcinomas ranged from 0% to 98%,
with a median value of 32%, which was selected as the cut-
off point for mtTFA expression. The mtTFA expression in
endometrioid adenocarcinomas was significantly associated
with the surgical stage, myometrial invasion, lymphovas-
cular space invasion, cervical invasion, and lymph node
metastasis. In contrast, no correlation between clinicopath-
ologic variables and mtTFA expression was found in
nonendometrioid carcinomas. Correlation analysis between
mtTFA and p53 expression by using the Pearson test
showed significant correlation in endometrioid adenocarci-
nomas (P=0.007), but no significant correlation in non-
endometrioid carcinomas (P=0.947). A univariate survival
analysis showed that the 10-year overall survival rate of the
patients with mtTFA-positive endometrioid adenocarcino-
ma was significantly worse than that of patients with
mtTFA-negative endometrioid adenocarcinoma (80.8% vs.
93.8%, P=0.012). However, the multivariate analysis
revealed that mtTFA expression in endometrioid adenocar-
cinomas was no independent prognostic factor. The positive
mtTFA expression is a useful maker for progression of the
tumors and the poor prognosis of the patients in endome-
trioid adenocarcinomas.
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Introduction
Endometrial carcinoma is the most common malignant
tumor of the female genital tract in the Western countries. A
dualistic model of endometrial carcinogenesis has been
proposed since the 1980s, based on light microscopic
appearance, clinical behavior, and epidemiology [1]. Type
I cancers, those with endometrioid histology, comprise
approximately 80% of all endometrial carcinomas. In
contrast, type II endometrial cancers have nonendometrioid
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clinical course. Hormonal risk factors have not been
identified. Common genetic changes in type I cancers
include microsatellite instability or specific mutation of
PTEN, K-ras, and β-catenin genes, while most type II
cancers contain mutations of p53 [2].
Mammalian mitochondrial transcription factor A
(mtTFA) proteins have a molecular weight of ∼25 kDa
and consist of an amino-terminal high mobility group
(HMG) domain, a basic linker region, a second HMG
domain, and a basic carboxyterminal tail [3]. It was recently
demonstrated that mtTFA, which was firstly identified as a
mitochondrial transcription factor, is involved in not only
the transcription of mitochondrial DNA (mtDNA) but also
the replication of mtDNA, recognition of mtDNA damage,
stabilization of mtDNA, and indirectly, in repair of mtDNA
[4].
SeveralstudiesshowedthatexpressionofmtTFAincreased
the amount of mtDNA in association with the total amount of
mtTFA in human cells [3, 5]. Maintenance of mtDNA copy
number and expression are considered to be essential for
preservation of mitochondrial function and cell growth via
the regulation of mtTFA [3, 6]. A quantitative study using
laser-captured microdissected tissues showed an increase of
mtDNA content in endometrioid adenocarcinomas [7].
Italian authors reported that 2-fold increase of the mtTFA
content was found in the endometrioid adenocarcinoma
samples compared to the proliferative control endometrial
samples [8]. The down-regulation of mtTFA was also
reported to be significantly associated with the disease
progress of colorectal cancer [9].
This study investigated the correlation between the
expression of mtTFA and the clinicopathological profile
of the patients with endometrial carcinoma and thus found
the mtTFA expression to be a useful maker for progression
of the tumors and the poor prognosis of the patients in
endometrioid adenocarcinomas.
Materials and methods
Case selection
The study included 276 Japanese patients with endometrial
carcinoma who had undergone surgery at University of
Occupational and Environmental Health hospital from 1990
to 2006. These included 245 cases of endometrioid
adenocarcinoma and 31 cases of nonendometrioid carcino-
ma (21 cases of serous carcinoma and 10 cases of clear cell
adenocarcinoma). All studied endometrial carcinoma speci-
mens were from hysterectomy specimens. Tumor grade and
stage were evaluated using FIGO criteria. The retroperito-
neal lymphadenectomy or sampling was performed in 211
patients with endometrioid adenocarcinoma and 20 patients
with nonendometrioid carcinoma.
Twenty-five control samples were obtained from 25
patients who underwent hysterectomy at University of
Occupational and Environmental Health hospital in 2008
for benign uterine lesions, including leiomyomas, adeno-
myosis, and uterine prolapse.
Immunohistochemistry
For immunohistchemistry, 4-μm sections were cut from
formalin-fixed paraffin-embedded tissue blocks, deparaffi-
nized in xylene, and rehydrated through sequential changes
of alcohol and distilled water. A polyclonal antibody
against mtTFA was generated by multiple immunization
of a New Zealand white rabbit using synthetic peptides, as
described previously (dilution 1:400) [10]. p53 was
detected using the ready-to-use p53 monoclonal antibody
(clone DO-7, DAKO, Kyoto, Japan). The slides for p53
were heated in an autoclave at 120°C for 5 min in 0.01 M
citrate buffer (pH=6.0) before the immunostaining. The
immunoreactivity for mtTFA was not changed by the
autoclave heating system. The slides for mtTFA and p53
were incubated with these antibodies for 2 h at room
temperature. The selected slides were incubated with
mtTFA antibody or mtTFA antibody+synthetic peptides
of mtTFA (40 μg) in order to check the specificity of
mtTFA immunostaining. Antibody binding was visualized
using the EnVision+ Dual link system and diaminobenzi-
dine as chromogen (Dako Cytomation, Kyoto, Japan). The
slides were counterstained with methyl green and mounted.
Interpretation of immunohistochemical preparations
Immunostained slides were analyzed independently by two
authors. Slight differences were resolved by simultaneous
viewing. The labeling indices (LI) of mtTFA and p53 were
defined as the percentage of the tumor cells with clear
cytoplasmic and nuclear immunoreactivity out of the total
number of the tumor cells, respectively. LI was determined
by counting at least 500 cells in the most active area of the
specimen. The cases for mtTFA and p53 were judged as
positive when more than 32% (median) and 50% of the
tumor cells [11] showed immunoreactivity, respectively.
Statistical analysis
Statistical analyses were carried out using SPSS for
Windows, version 16.0.0 (SPSS, Chicago, IL, USA). The
Mann–Whitney U test was used for comparison of
clinicopathological variables with positive and negative
mtTFA expression. The degree of correlation between the
p53 and mtTFA expression was evaluated using the Pearson
388 Virchows Arch (2010) 456:387–393test. The survival time was calculated from date of the
initial surgery. The cumulative 10-year survival was
determined using the Kaplan–Meier product-limited meth-
od. The log-rank test was used to test the differences in
survival within variables. The Cox proportional hazards
model was used to identify and simultaneously evaluate any
independent prognostic factors associated with relative
survival. Statistical significance was considered to exist at
a value of P<0.05.
Results
Clinicopathologic features
Two hundred and forty-five patients with endometrioid
adenocarcinoma ranged in age from 27 to 82 years. The
mean age was 56.5 years. One hundred and nineteen cases
(48.6%) had tumor grade 1, 82 cases (33.4%) grade 2 and
44 cases (18.0%) grade 3. FIGO stages of these 245
endometrioid adenocarcinomas were 59 patients (24.1%)
with stage Ia disease, 87 patients (35.5%) with stage Ib
disease, 23 patients (9.4%) with stage Ic disease, seven
patients (2.9%) with stage IIa disease, 11 patients (4.5%)
with stage IIb disease, 25 patients (10.2%) with stage IIIa
disease, three patients (1.2%) with stage IIIb disease, 26
patients (10.6%) with stage IIIc disease, and four patients
(1.6%) with stage IV disease.
The age of the 31 patients with nonendometrioid
adenocarcinoma ranged from 53 to 81 years with a mean
age of 67.1 years. Among these 31 cases of nonendome-
trioid adenocarcinoma with clinicopathologic stage
assessed, six cases (19.3%) were diagnosed with stage Ia
disease, five (16.1%) stage Ib disease, three (9.7%) stage
Ic disease, three (9.7%) stage IIa disease, three (9.7%) IIb
disease, four (12.9%) stage IIIa disease, one (3.2%) stage
IIIb disease, three (9.7%) stage IIIc disease, and three
(9.7%) stage IV disease.
The age of the 25 control patients ranged from 32 to
72 years. Of these 25 cases, 10 had proliferative, 10
secretory, and five atrophic endometria.
Immunohistochemical findings
mtTFA expression
mtTFA showed only cytoplasmic expression (Fig. 1). The
specificity of this mtTFA polyclonal antibody was tested by
immunohistochemisry. After incubation of this antibody
with the excess of synthesized peptides of mtTFA, the
positive immunostaining was almost abolished (Fig. 2). Of
245 endometrioid adenocarcinomas, the mean mtTFA index
Fig. 1 Immunohistochemical positive mtTFA expression in grade 2
endometrioid adenocarcinoma. ×400
Fig. 2 Immunohistochemical
mtTFA expression in grade 1
endometrioid adenocarcinoma
after incubation of an anti-
mtTFA polyclonal antibody
(a) or an anti-mtTFA polyclonal
antibody+synthesized peptides
of mtTFA (b). ×200
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expression (LI≥32%) was found in 52 (43.7%) of 119
grade 1 tumors, 43 (52.4%) of 82 grade 2 tumors, and 28
(63.6%) of 44 grade 3 tumors. The mtTFA expression
correlated significantly with the surgical stage, myometrial
invasion, lymphovascular space invasion (LVSI), cervical
invasion, lymph node metastasis, and p53 expression but
did not correlate with age of the patients, grade of the
tumor, and ovarian metastasis (Table 1).
The positive cytoplasmic staining for mtTFA was shown
in 17 (54.8%) of 31 nonendometrioid carcinomas (11 of 21
serous carcinomas and six of 10 clear cell adenocarcino-
mas). There was no significant correlation between mtTFA
expression and any clinicopathologic variables in non-
endometrioid carcinomas.
Of the 25 control cases, the cytoplasmic staining for
mtTFA was positive for the vascular endothelial cells and
was negative in the stromal cells and the atrophic
endometrial glands. The proliferative and secretory endo-
metrial glands and the smooth muscle cells were weakly
positive for mtTFA.
p53 expression
Positive immunohistochemical reaction for p53 in tumor
cells was characterized by positive staining seen in the
Table 1 Clinicopathologic variables and mtTFA expression
Variable mtTFA in mtTFA in
Endometrioid adenocarcinomas Nonendometroioid carcinomas
Positive Negative P value Positive Negative P value
n=123 n=122 n=17 n=14
Age 0.376 0.608
<60 years 76 82 4 2
≥60 years 47 40 13 12
Stage 0.008 0.197
I and II 85 102 13 7
III and IV 38 20 4 7
Grade 0.050
1 and 2 95 106
32 8 1 6
Myometrial invasion <0.001 0.175
≥1/2 78 103 11 5
>1/2 45 19 6 9
LVSI 0.006 0.953
− 68 88 7 6
+5 5 3 41 0 8
Cervical invasion 0.015 0.983
− 97 110 12 10
+2 6 1 2 5 4
Ovarian metastasis 0.542 0.856
− 109 111 14 12
+1 4 1 1 3 2
Lymph node metastasis
a 0.003 0.672
− 87 100 8 7
+1 9 5 2 3
LI ofp53 expression 0.003 0.73
<50% 98 113 2 1
≥50% 25 9 15 13
mtTFA mitochondrial transcription A, LVSI lymphovascular space invasion, LI labeling index
aThe retroperitoneal lymph node adenectomy or sampling was done in 211 endometrioid cases and 20 nonendometrioid cases
390 Virchows Arch (2010) 456:387–393nucleus (Fig. 3). Among 245 endometrioid adenocarcino-
mas, the range of LI for p53 expression was from 0% to
98%. Seventy-seven tumors (31.4%) demonstrated in 0% of
LI, 41 (16.7%) tumors in 1–9% of LI, 92 (37.6%) tumors in
10–49% of LI, and 35 (14.3%) tumors in ≥50% of LI.
Among 31 nonendometrioid carcinomas, the range of LI for
p53 expression was from 20% to 98%. Three tumors
(9.7%) demonstrated in 20–49% of LI and 28 (90.3%)
tumors in ≥50% of LI. Correlation analysis between mtTFA
and p53 expression by using the Pearson test showed
significant correlation in endometrioid adenocarcinomas
(P=0.007), but no significant correlation in nonendometrioid
carcinomas (P=0.947). All 25 samples of morphologically
benign endometrium evaluated were negative for p53.
Prognosis
Figure 4 shows the Kaplan–Meier survival curve for 211
patients with endometrioid adenocarcinoma, who were
performed the retroperitoneal lymphadectomy or sampling.
The 10-year overall survival rate of patients with mtTFA-
negative endometrioid adenocarcinoma was 93.8%. In
contrast, the 10-year survival rate of patients with mtTFA-
positive endometrioid adenocarcinoma was 80.8%. Patients
with mtTFA-positive endometrioid tumor showed a lower
long-term survival rate in comparison to patients with
mtTFA-negative endometrioid tumor (P=0.012, log-rank
test). The 10-year overall survival rates of patients with
p53-negative (LI<50%) and p53-positive (LI≥50%) endo-
metrioid adenocarcinomas was 89.9% and 72.2% (P<0.03,
log-rank test). A univariate analysis showed that age of the
patients, the grade of the tumor, myometrial invasion,
LVSI, cervical invasion, ovarian metastasis, lymph node
metastasis, p53 expression, and mtTFA expression were
significantly associated with survival (Table 2). In a
multivariate analysis using the Cox proportional hazards
model, the significance of myometrial invasion and lymph
node metastasis was preserved, whereas the significance of
the age of the patients, the grade of the tumor, LVSI,
cervical invasion, ovarian metastasis, p53 expression, and
mtTFA expression disappeared.
Of 31 patients with nonendometrioid carcinoma, the
10-year overall survival rates of patients with mtTFA-
negative tumor and with mtTFA-positive tumor were 42.3%
and 61.2%, respectively (P=0.40, log-rank test). In a
univariate analysis, the significance of surgical stage, LVSI,
and ovarian metastasis was demonstrated (P=0.001, 0.014,
and 0.006, respectively), whereas the significance of age of
the patients, myometrial invasion, cervical invasion, lymph
node metastasis, p53 expression, and mtTFA expression
was not demonstrated.
Discussion
In the present study, a univariate survival analysis showed
that the survival rate of patients with mtTFA-negative
endometrioid adenocarcinoma was significantly better than
that for patients with mtTFA-positive endometrioid adeno-
carcinoma. The mtTFA expression was significantly asso-
ciated with unfavorable histopathological variables of
endometrioid adenocarcinomas including an advanced
stage. The increases of mtDNA content [7] or mtTFA [8]
were reported in endometrioid adenocarcinomas. The
mtDNA copy number is suggested to be increased by a
feedback mechanism that compensates for defects in
mitochondria harboring mutated mtDNA and a defective
respiratory system [12]. The inhibition of mtTFA activity
Fig. 3 Immunohistochemical positive p53 expression in serous
carcinoma. ×100
Fig. 4 Comparison of the overall survival rates in 211 patients with
endometrioid adenocarcinoma according to mtTFA expression
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oxidative stress.
The mitochondria produce cellular energy by oxidative
phosphorylation and generate reactive oxygen species
(ROS) as a by-product. The mitochondrial genome exhibits
higher mutation rates than the nuclear genome and is highly
susceptible to damage caused by ROS [13]. Oxidative
stress and resultant mtDNA mutations have been suggested
to underlie the development and/or maintenance of the
malignant phenotype [14]. The D-loop region of mtDNA is
a hotspot for somatic mutations in human cancers [14]. A
somatic D-loop mtDNA mutation was found in five
(62.5%) of eight uterine serous carcinomas [15]. Authors
suggested that oxidative damage is an important mecha-
nism in the development of serous carcinoma. The mtTFA
expression of nonendometrioid carcinomas was not associ-
ated with the clinicopathologic variables and prognosis of
the patients. In contrast, the mtTFA expression of endome-
trioid adenocarcinomas was significantly associated with
the clinicopathologic variables and prognosis of the
patients. A large study for nonendometrioid carcinoma is
necessary to resolve this question. There is no literature
concerning with the incidence of mtDNA mutation in
endometrioid adenocarcinomas or correlation between
mtTFA expression and mutation of mtDNA.
Using a p53 index of ≥50% as a cut-off between positive
and negative p53 staining, immunohistochemical staining
for p53 was reported to be a significant prognostic indicator
in patients with endometrioid adenocarcinoma [11]. This
result was confirmed in the present study. The aggressive
clinical course and high p53 expression of nonendometrioid
carcinomas were also confirmed. Yoshida et al. suggested
that the physical and functional interaction of p53 with
mtTFA play an important role in apoptosis [10]. An
increased apoptosis was observed in mtTFA knockout
animals, thus suggesting that mtTFA is involved in
apoptosis [16]. The cell lines of radio-resistant oral
squamous cell carcinoma strongly expressed mtTFA in
comparison to those of the radio-sensitive oral squamous
cell carcinoma [17]. Chemotherapy and radiation treatment
of cancer are intended to induce apoptosis in tumor cells. It
is interesting that correlation analysis between mtTFA and
p53 expression by using the Pearson test showed significant
correlation in endometrioid adenocarcinomas.
In conclusion, the positive mtTFA expression is a useful
maker for the progression of the tumors and the poor
prognosis of the patients in endometrioid adenocarcinomas.
Immunohistochemical expression of p53 was a prognostic
indicator in patients with endometrioid adenocarcinoma.
The mtTFA activity of endometrioid adenocarcinomas may
play a different role from that of nonendometrioid carcino-
mas, through initiation and/or progression of the cancerous
processes.
Conflict of interest statement We declare that we have no conflict
of interest.
Variables Univariate analysis Multivariate analysis
HR 95%CI P value HR 95%CI P value
Age
<60 vs. ≥60 years 2.742 1.134–6.630 0.025 1.527 0.602–3.874 0.373
Grade
1 and 2 vs. 3 3.476 1.419–8.513 0.006 1.235 0.339–4.505 0.749
Myometrial invasion
≥1/2 vs. >1/2 17.997 5.272–61.438 <0.001 6.545 1.517–28.246 0.012
LVSI
Negative vs. positive 5.876 2.133–16.183 <0.001 0.969 0.232–4.037 0.965
Cervical invasion
Negative vs. positive 4.560 1.815–11.458 0.001 1.085 0.306–3.843 0.899
Ovarian metastasis
Negative vs. positive 5.955 2.373–14.941 <0.001 3.065 0.988–9.504 0.052
Lymph node metastasis
Negative vs. positive 15.738 6.401–38.693 <0.001 4.954 1.510–16.256 0.008
p53
LI<50% vs. LI≥50% 2.921 1.117–7.638 0.029 0.960 0.254–3.821 0.952
mtTFA
LI<32% vs. LI≥32% 3.395 1.232–9.358 0.018 1.224 0.403–3.719 0.722
Table 2 Uni- and multivariate
analyses of prognostic variables
for overall survival of the
patients with endometrioid ade-
nocarcinoma by Cox propor-
tional hazards model
LVSI lymphovascular space in-
vasion, mtTFA mitochodrial
transcription factor A, HR haz-
ard ratio, LI labeling index, 95%
CI 95% confidence interval
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